Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate …

Background The phase 3 SPARTAN study evaluated apalutamide versus placebo in
patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …